NRx Pharmaceutical’s Chairman and Chief Executive Officer Jonathan Javitt to Present Company Business Update at H.C. Wainwright 7th Annual Israel Conference
NRx Pharmaceuticals (NASDAQ: NRXP) has announced that its CEO, Jonathan Javitt, will present updates on the company’s business during the H.C. Wainwright 7th Annual Israel Virtual Conference on November 15, 2021, at 1:30 PM EST. The presentation can be accessed through a provided link. NRx is known for its investigational product ZYESAMI®, aimed at treating COVID-19 and currently in phase 3 trials supported by various US government bodies. The company is also advancing NRX-101 for treating suicidal bipolar depression, with readouts expected in 2022.
- None.
- None.
Conference Begins on November 15, 2021
RADNOR, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today announced its Chairman of the Board and Chief Executive Officer, Jonathan Javitt, will be presenting updates to the Company’s business at the H.C. Wainwright 7th Annual Israel Virtual Conference.
Details of the presentation can be found below:
Date: Monday, November 15, 2021
Time: 1:30 PM EST
Link to Presentation: https://journey.ct.events/view/29d54135-a44e-4fd3-a9b8-03b0a5834395
About NRx Pharmaceuticals
NRx Pharmaceuticals (www.nrxpharma.com) (NRx) draws upon more than 300 years of collective, scientific, and drug-development experience to bring improved health to patients. Its investigational product, ZYESAMI® (aviptadil) for patients with COVID-19, has been granted Fast Track designation by the US Food and Drug Administration (FDA) and is currently undergoing phase 3 trials funded by the US National Institutes of Health, the Biomedical Advanced Research and Development Authority part of the US Department of Health and Human Services, and the Medical Countermeasures program, part of the US Department of Defense. The FDA has additionally granted Breakthrough Therapy Designation, a Special Protocol Agreement, and a Biomarker Letter of Support to NRx for NRX-101, an investigational medicine to treat suicidal bipolar depression. NRX-101 is currently in Phase 3 trials, with readouts expected in 2022. In July 2021, the Government of Israel awarded NRx the exclusive worldwide right to develop and market the BriLife™ COVID vaccine developed by the Israel Institute for Biological Research.
NRx is led by executives who have held senior roles at Allergan, J&J, Lilly, Novartis, Pfizer, and the US FDA. NRx is chaired by Prof Jonathan Javitt, MD, MPH, who has held leadership roles in six biotechnology startup companies with public exits and been appointed to advisory roles in four US Presidential administrations. The NRx board includes Dr. Sherry Glied, former US Assistant Secretary for Health (ASPE), Daniel E. Troy, JD, former Chief Counsel of the US FDA, Chaim Hurvitz, former director of Teva and President of the Teva International Group, and General H.R. McMaster, Ph.D. (US Army, Ret.) the 26th United States National Security Advisor.
Cautionary Note Regarding Forward-Looking Statements
This announcement of NRx Pharmaceuticals, Inc. includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the Company’s strategies, plans, objectives, and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the Company’s management.
The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above.
CORPORATE CONTACT:
Jack Hirschfield – Head of Corporate Communications, NRx
jhirschfield@nrxpharma.com
INVESTOR RELATIONS
Eric Goldstein
Managing Director – LifeSci Advisors
egoldstein@lifesciadvisors.com
FAQ
When will NRx Pharmaceuticals present at the H.C. Wainwright Conference?
What is ZYESAMI® and its current status?
What are the key products NRx Pharmaceuticals is developing?
Who will present the business updates during the conference?
Where can I find the link for NRx Pharmaceuticals' presentation?
